A single 60 mg dose of ARV-102 reduced LRRK2 protein by over 50% in cerebrospinal fluid and 90% in peripheral blood mononuclear cells. The Phase 1 trial showed ARV-102 was well tolerated ...

Arvinas, Inc., a biotechnology company focused on targeted protein degradation therapies, announced that new preclinical data for its investigational drug ARV-393 will be presented at the upcoming ...